Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

3 results

  • Neonatal onset of bipolar spectrum disorder through a three-generation familial study

  • B. Abdelmoula, S. Sellami, M. Keskes, N. Bouayed Abdelmoula
  • Journal:
    European Psychiatry / Volume 65 / Issue S1 / June 2022
    Published online by Cambridge University Press:
    01 September 2022, pp. S407-S408
    • Article
      • You have access
      • Open access
    • PDF
    • Export citation
  • Introduction

    Age at onset of pediatric bipolar spectrum disorder (BSD) is an important marker of a more severe form and a highly heritable mood/mental disorder.

    Objectives

    Here, we report a familial Tunisian BSD follow-up study showing a very early onset of the BSD at the neonatal period.

    Methods

    A 28-year-old female and her 30-year old sister were referred for genetic and psychological assessments due to recurrent depressive episodes.

    Results

    Psychological assessment revealed a BSD type II with episodes of hypomania for both patients. The 30-year old sister presented a mixed form of BSD coupled with autistic traits, hyposomnia and obsessive-compulsive behaviors. Intellectual and cognitive abilities were without concerns. Familial history revealed BDS among paternal relatives including the brothers’ and sisters’ father as well as all their uncles offspring’s, and their grandparents, who were consanguineous. The depressive mood was a common sign in the three generations. Personal history revealed significant signs of a very early onset of the disorder since the neonatal period for the two sisters as well as for their four paternal cousins who also presented BSD features. Familial risk of BSD in this family correlates with a variably higher personal risk of other psychiatric disorders such as anxiety, drug abuse, personality disorders, and autism spectrum disorder.

    Conclusions

    Environmental conditions, familial care and educational level have a strong correlation with the severity and the efficiency of cognitive management of BSD and its psychiatric comorbidities. BSD is highly heterogeneous and polygenic and personalized management has considerable clinical repercussions benefits.

    Disclosure

    No significant relationships.

  • 20 - Interpersonal therapy

  • from Section 3 - Psychotherapies for mood disorders
  • Edited by J. John Mann, Columbia University, New York
  • Edited in association with Patrick J. McGrath, Columbia University, New York, Steven P. Roose, Columbia University, New York
  • Book:
    Clinical Handbook for the Management of Mood Disorders
    Published online:
    05 May 2013
    Print publication:
    09 May 2013, pp 270-279

  • Summary

    This chapter reviews the developmental epidemiology, and determinants of course and outcome of pediatric depression. Early-onset depression conveys significantly increased risk, compared to later-onset depression for the development of bipolar spectrum disorder. Parents have a right to know the goals and progress of treatment. A high proportion of clinically referred youth with mood disorders have clinically significant suicidal ideation or behavior. Multi-family psychoeducation and family-based attachment therapy show promise in randomized clinical trials. Two selective serotonin reuptake inhibitors, fluoxetine and escitalopram are approved for use in adolescent depression by the Federal Drug Administration (FDA); fluoxetine is also approved for use in preadolescent patients. Patients with co-morbid anxiety or obsessive compulsive disorder (OCD) can usually be treated with the same antidepressant as that used for the depression, although higher dosages may be needed to treat anxiety or OCD.